Bharat Biotech expects peer review of Covaxin’s Phase 3 trials data in Q4 2021

0
Bharat Biotech, which is yet to publish the data of its COVID-19 vaccine Covaxin phase-3, expects a peer review of the jab in two to four months after it was given to scientific journals, said Raches Ella, Project Lead, COVID-19 Vaccine at Bharat Biotech on Wednesday. In a series of tweets, Ella said there were nine publications on Covaxin so…
« Previous post: | Next post: »